Genentech

Beiträge: 4
Zugriffe: 1.683 / Heute: 1
Genentech kein aktueller Kurs verfügbar
 
Genentech first-henri
first-henri:

Genentech

 
09.07.03 22:25
#1
09 JUL 22:24 AFX *GENENTECH Q2 FIRST CALL EST. 26C
09 JUL 22:23 ADE Aktien NASDAQ Schluss: Technologiebörse rutscht im späten Handel ins Minus  
09 JUL 22:23 AFX *GENENTECH Q2 EARNS 31C VS. 23C
Genentech first-henri
first-henri:

.

 
09.07.03 22:27
#2
09 JUL 22:26 AFX *RPT GENENTECH Q2 EARNS 31C VS. 23C
09 JUL 22:24 AFX *GENENTECH Q2 REVS $799.7 MLN VS. $622.3 MLN
Genentech Börsenmonster
Börsenmonst.:

..

 
09.07.03 22:30
#3
Genentech (WKN: 924632, US: DNA) meldet für das abgelaufene zweite Quartal einen Gewinn je Aktie von 31 Cents (Prognose: 26 Cents) nach 23 Cents im Vorjahr. Der Reingewinn lag bei $132.3 Millionen oder 25 Cents je Aktie nach einem Verlust von 41 Cents im Vorjahr. Im Vorjahresergebnis war ein Sonderaufwand in Höhe von $518 Millionen für die Begleichung von Rechtskosten eingerechnet. Der Umsatz mit dem Medikament Rituxan wuchs um 32%. Insgesamt wuchs der Umsatz um 29% auf $799.7 Millionen. Die Aktie verliert nachbörslich um 0.36% auf $77.

Genentech first-henri

.

 
#4
Genentech Q2 profit boosted by Anti-cancer drugs sales 09.07.2003 23:22    Headlines


   BOSTON (AFX) -- Genentech swung to a second-quarter profit, boosted by
higher sales of its flagship anti-cancer drug, Rituxan, the No. 2 biotech firm
reported Wednesday.
   South San Francisco, Calif.-based Genentech said it earned $132.3 million,
or 25 cents per share. In the 2002 second quarter, Genentech had a net loss of
$213.6 million, or 41 cents per share. Excluding special charges, Genentech said
it earned $163.5 million, or 31 cents per share, well ahead of the 26 cents per
share that analysts, on average, expected, according to Reuters Research.
   Shares of Genentech  added 2 cents to $77.40 in recent after-hours dealings
Genentech said second-quarter revenue rose 29 percent to $799.7 million,
highlighted by sales of anti-cancer drugs Rituxan and Herceptin. Rituxan, which
is used in the treatment of non-Hodgkin's lymphoma, had sales of $363.4 million
compared with $274.9 million in the year-earlier period.
   Genentech co-markets Rituxan in the United States with San Diego-based
biotech Idec Pharmaceuticals . Shares of Idec eased 1 cent to $38.55.
Sales of Herceptin, used to fight breast cancer, were $109.1 million, up from
$95.1 million in the same period in 2002.
   Genentech's stock has been at the forefront of a rally in biotech stocks
this year because of investors' optimism about the company's experimental
anti-cancer drug, Avastin.
   Genentech on Wednesday said it's on track to complete its marketing
application for Avastin by the end of September. The company anticipates an FDA
decision "no later than the end of the first quarter of 2004."
   In May, Genentech said Avastin did better than expected at extending the
lives of patients with advanced colon cancer.
   




Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Genentech Forum

  
Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
4 60 Cancer Drugs to watch: geldschneider 906866 A 26.07.17 22:47
  1 Genentech 48 % Gewinnsteigerung dank Krebs-"Drugs" Mme.Eugenie pacorubio 14.03.08 11:01
40 2.864 MophoSys - ExtraChancen ecki templer 03.01.07 01:28
  81 Depotwettbewerb USA 21 KW Eskimato Eskimato 05.11.03 07:30
  3 Genentech first-henri first-henri 09.07.03 23:24

--button_text--